Novo Nordisk Stock Hits Record High as Wegovy Maker Sees Up To 26% Sales Growth This Year

The American depositary receipts (ADRs) of Novo Nordisk (NVO), the market leader in weight-loss drugs, rose sharply in early trading Wednesday, hitting an all-time high, after the Danish company said it expects sales growth this year of between 18% and 26% in constant exchange terms.The company also reported better-than-forecast sales that were 36% higher last year at 232.3 billion kroner ($33.8 billion) on the back of buoyant demand for its weight loss drug Wegovy and diabetes drug Ozempic. "Our focus in 2 ...